Literature DB >> 15657522

General aspects and specific issues of informed consent on breast cancer treatments.

Miyuki Takasugi1, Eriko Iwamoto, Sadako Akashi-Tanaka, Takayuki Kinoshita, Takashi Fukutomi, Kohichi Kubouchi.   

Abstract

Informed consent (IC) is the process by which a patient can make choices about his/her health care; therefore it is considered to be a voluntary authorization given by the patient to the physician. To ensure the patient's right to self-determination, what can the physicians do? When treating breast cancer, there are several specific issues that must be clarified by the IC. We have selected and evaluated the basic elements of IC and mentioned the basic concepts of IC in details. First of all, complete information must be disclosed to the patient (physician's responsibility for medical accountability). The information to be disclosed is summarized in the following three elements: 1) The nature of the treatment/procedure, 2) The relevant risks/benefits, and 3) Reasonable alternatives to the proposed intervention (alternative treatments/procedures). However, the physician is not obliged to persuade the patient to accept the proposed intervention. IC information should be documented in detail on the patient's chart without delay. These issues include IC regarding surgical procedures (mastectomy or breast conservation treatment), IC regarding clinical studies (description of randomized controlled trials), IC regarding genetic diagnosis (ethical issues), and the like. IC means informed decision-making, close relationships between physicians and patients are needed.

Entities:  

Keywords:  Professional Patient Relationship

Mesh:

Year:  2005        PMID: 15657522     DOI: 10.2325/jbcs.12.39

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  2 in total

1.  Breast cancer patients' treatment expectations after exposure to the decision aid program adjuvant online: the influence of numeracy.

Authors:  Isaac M Lipkus; Ellen Peters; Gretchen Kimmick; Vlayka Liotcheva; Paul Marcom
Journal:  Med Decis Making       Date:  2010-02-16       Impact factor: 2.583

2.  Outcome analysis of primary breast cancer patients who declined adjuvant chemotherapy-results from the prospective multi-center BRENDA II study.

Authors:  Elena Leinert; Lukas Schwentner; Wolfgang Janni; Achim Wöckel; Saskia-L Herbert; Daniel Herr; Thorsten Kühn; Felix Flock; Ricardo Felberbaum; Rolf Kreienberg; Visnja Fink; Davut Dayan; Kristina Ernst; Susanne Singer
Journal:  Breast Cancer       Date:  2022-02-18       Impact factor: 3.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.